Elevated Cholesterol
Conditions
Brief summary
Elevated blood lipid levels are one of the main risk factors for cardiovascular disease. To manage elevated blood lipid levels in otherwise healthy people at low risk of cardiovascular disease, lifestyle changes are recommended as the first treatment strategy. One of these changes concerns diet. Clinical observations by general practitioners in alpine regions of Switzerland have shown that consumption of dairy products produced from cows living and grazing at high altitudes can have a beneficial effect on blood lipid parameters. However, little clinical data is available on the effect of alpine dairy products on health-related markers. This pilot study aims to assess if replacing standard (non-alpine) dairy products by alpine dairy products in the daily diet among patients with elevated LDL-cholesterol levels could reduce the blood LDL-cholesterol levels.
Interventions
OTHERAlpine dairy products
The intervention group will be instructed to eat three portions of alpine dairy products daily. The proposed three portions represent an estimated mean consummation in the study population, taking into consideration the national statistics.
Sponsors
University of Fribourg
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old * Elevated lipid levels, namely: fasting LDL-cholesterol \>3mmol/L and \</=5mmol/L * Agreeing to eat 3 portions of dairy products daily (according to instructions)
Exclusion criteria
* Eating less than two and more than six portions of dairy products daily * Body weight change +/-5% of body weight in the last three months * Secondary prevention treatment for cardiovascular disease * Moderate, high or very high cardiovascular risk according to AGLA score * Currently taking PSCK9-inhibitors, ezetimibe, statins, glucocorticoids * Poorly controlled, severe chronic renal insufficiency, hypothyroidism, cholestasis, nephrotic syndrome, eating disorders, alcohol abuse, Cushing syndrome * Myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting in the previous 6 months * Known lactose intolerance or dairy allergies * Change of diet less than 2 months before intervention * Pregnant or breastfeeding * Incapacity of judgement * Inability to speak and read German
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in fasting blood LDL-cholesterol level | Baseline, Day 15, Day 30 and Day 45 | Measure of LDL-cholesterol in mmol/L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in total cholesterol, triglycerides, HDL-cholesterol and lipoprotein A | Baseline, Day 15, Day 30 and Day 45 | Measures in mmol/L |
Countries
Switzerland
Outcome results
None listed